Regulatory authorities have approved a new formulation of thyroxin, promising improved efficacy for thyroid disorder patients. Details are still emerging.
Genflow Biosciences experiences a surge in worldwide coverage, with 24 mentions in recent media monitoring, signaling increased public and industry interest.
Neurocrine Biosciences sees a significant increase in international media mentions, indicating heightened interest or developments in the company’s activities.